Session

Liver & biliary (Posters)

PROTEASE-DEPENDENT LOSS OF INTESTINAL EPITHELIAL INTEGRITY IN SPONTANEOUS BACTERIAL PERITONITIS
PROTEASE-DEPENDENT LOSS OF INTESTINAL EPITHELIAL INTEGRITY IN SPONTANEOUS BACTERIAL PERITONITIS

ELEVATED LIVER AMINOTRANSFERASES LEVEL AND COVID-19 PROGNOSIS
ELEVATED LIVER AMINOTRANSFERASES LEVEL AND COVID-19 PROGNOSIS

PROGNOSIS OF HEPATOCELLULAR CARCINOMA IN POST VIRAL CIRRHOSIS : PERFORMANCE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO AND THE PLATELET-TO-LYMPHOCYTE RATIO
PROGNOSIS OF HEPATOCELLULAR CARCINOMA IN POST VIRAL CIRRHOSIS : PERFORMANCE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO AND THE PLATELET-TO-LYMPHOCYTE RATIO

DISTINCT EFFECTS OF IGFBP2 ON VIABILITY OF HEPATOMA CELLS - A MATTER OF DOSE
DISTINCT EFFECTS OF IGFBP2 ON VIABILITY OF HEPATOMA CELLS - A MATTER OF DOSE

NOVEL PATHOGENIC ALG8 VARIANTS AND EVIDENCE FOR SOMATIC LOSS OF HETEROZYGOSITY IN 199 AUTOSOMAL DOMINANT POLYCYSTIC LIVER DISEASE PATIENTS
NOVEL PATHOGENIC ALG8 VARIANTS AND EVIDENCE FOR SOMATIC LOSS OF HETEROZYGOSITY IN 199 AUTOSOMAL DOMINANT POLYCYSTIC LIVER DISEASE PATIENTS

THE SHIFT IN PREVALENCE, INCIDENCE, AND MORTALITY RATES OF VIRAL HEPATITIS TYPES A, B, C AND D IN BRAZILIAN CITIZENS BETWEEN 1999 AND 2019
THE SHIFT IN PREVALENCE, INCIDENCE, AND MORTALITY RATES OF VIRAL HEPATITIS TYPES A, B, C AND D IN BRAZILIAN CITIZENS BETWEEN 1999 AND 2019

CAN SERUM FERRITIN PREDICT 30 DAYS MORTALITY IN PATIENTS WITH DECOMPENSATED CIRRHOSIS?
CAN SERUM FERRITIN PREDICT 30 DAYS MORTALITY IN PATIENTS WITH DECOMPENSATED CIRRHOSIS?

PROCALCITONIN, NONALCOHOLIC FATTY LIVER DISEASE AND GUT MICROBIOME
PROCALCITONIN, NONALCOHOLIC FATTY LIVER DISEASE AND GUT MICROBIOME

NEW TOOLS FOR PREDICTING SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB
NEW TOOLS FOR PREDICTING SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB

DISTINCTIVE CLINICAL FEATURES OF NON-ALCOHOLIC AND MIXED FATTY LIVER DISEASE
DISTINCTIVE CLINICAL FEATURES OF NON-ALCOHOLIC AND MIXED FATTY LIVER DISEASE

INTERNATIONAL FRENCH-SPEAKING MULTICENTRE PRACTICE SURVEY ON HEPATIC HYDROTHORAX (HH) : RESULTS OF THE "HEP HEP" STUDY AMONG 529 HEPATOGASTROENTEROLOGIST (HG) OR PNEUMOLOGIST (PN) RESPONDENTS
INTERNATIONAL FRENCH-SPEAKING MULTICENTRE PRACTICE SURVEY ON HEPATIC HYDROTHORAX (HH) : RESULTS OF THE "HEP HEP" STUDY AMONG 529 HEPATOGASTROENTEROLOGIST (HG) OR PNEUMOLOGIST (PN) RESPONDENTS

WHAT IS THE CLINICAL IMPACT OF ASCITES CHOLESTEROL AND PROBNP LEVELS IN OUR ROUTINE PRACTICE FOR THE DIFFERENTIAL DIAGNOSIS OF ASCITES ETIOLOGY?
WHAT IS THE CLINICAL IMPACT OF ASCITES CHOLESTEROL AND PROBNP LEVELS IN OUR ROUTINE PRACTICE FOR THE DIFFERENTIAL DIAGNOSIS OF ASCITES ETIOLOGY?

PREDICTION OF ESOPHAGEAL VARICES IN PATIENTS WITH COMPENSATED ADVANCED CHRONIC LIVER DISEASE: EXTERNAL VALIDATION OF COOK COUNTY SCORE
PREDICTION OF ESOPHAGEAL VARICES IN PATIENTS WITH COMPENSATED ADVANCED CHRONIC LIVER DISEASE: EXTERNAL VALIDATION OF COOK COUNTY SCORE

UNDERSTANDING THE TRANSCRIPTOMIC CHANGES OF MAFLD IN HIGH FAT DIET MURINE MODELS AND ITS REVERSION BY ANTI-STEATOTIC TREATMENTS THROUGH META-ANALYSIS
UNDERSTANDING THE TRANSCRIPTOMIC CHANGES OF MAFLD IN HIGH FAT DIET MURINE MODELS AND ITS REVERSION BY ANTI-STEATOTIC TREATMENTS THROUGH META-ANALYSIS

Liver & biliary (Posters)  et al.

ACCURACY OF FIB-4 AND HEPAMET FIBROSIS SCORE TO IDENTIFY ADVANCED LIVER FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
ACCURACY OF FIB-4 AND HEPAMET FIBROSIS SCORE TO IDENTIFY ADVANCED LIVER FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

PREVALENCE AND RISK FACTORS ASSOCIATED WITH PROGRESSION TO ADVANCED FIBROSIS AND CIRRHOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): ANALYSIS OF A PROSPECTIVE REGISTRY
PREVALENCE AND RISK FACTORS ASSOCIATED WITH PROGRESSION TO ADVANCED FIBROSIS AND CIRRHOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): ANALYSIS OF A PROSPECTIVE REGISTRY

THE SYSTEMIC INFLAMMATORY RESPONSE IDENTIFIES PATIENTS WITH ADVERSE CLINICAL OUTCOME FROM IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA
THE SYSTEMIC INFLAMMATORY RESPONSE IDENTIFIES PATIENTS WITH ADVERSE CLINICAL OUTCOME FROM IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA

ASSOCIATION OF GLUTATHIONE-S-TRANSFERASE GENES DELETION POLYMORPHISM WITH THE ECHOCARDIOGRAPHIC PREDICTORS OF MYOCARDIAL HYPERTROPHY IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS
ASSOCIATION OF GLUTATHIONE-S-TRANSFERASE GENES DELETION POLYMORPHISM WITH THE ECHOCARDIOGRAPHIC PREDICTORS OF MYOCARDIAL HYPERTROPHY IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS

DIETARY PATTERNS IN PATIENTS WITH SIMPLE STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS: PROSPECTIVE COMPARATIVE TRIAL
DIETARY PATTERNS IN PATIENTS WITH SIMPLE STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS: PROSPECTIVE COMPARATIVE TRIAL

MICRORNA-122 CONJUGATED POLYMER NANOPARTICLES AS A PROTECTIVE TOOL AGAINST DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN AN EXPERIMENTAL MODEL
MICRORNA-122 CONJUGATED POLYMER NANOPARTICLES AS A PROTECTIVE TOOL AGAINST DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN AN EXPERIMENTAL MODEL

Item 81 - 100 / 270
1 2 3 4
5
6 7 8 9 10 11 12 13 14